These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 30553477)

  • 41. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
    Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting BAP1: a new paradigm for mesothelioma.
    Schunselaar LM; Zwart W; Baas P
    Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
    Bott M; Brevet M; Taylor BS; Shimizu S; Ito T; Wang L; Creaney J; Lake RA; Zakowski MF; Reva B; Sander C; Delsite R; Powell S; Zhou Q; Shen R; Olshen A; Rusch V; Ladanyi M
    Nat Genet; 2011 Jun; 43(7):668-72. PubMed ID: 21642991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
    Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
    Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
    Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.
    Betti M; Casalone E; Ferrante D; Romanelli A; Grosso F; Guarrera S; Righi L; Vatrano S; Pelosi G; Libener R; Mirabelli D; Boldorini R; Casadio C; Papotti M; Matullo G; Magnani C; Dianzani I
    Genes Chromosomes Cancer; 2015 Jan; 54(1):51-62. PubMed ID: 25231345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
    Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
    Hu ZI; Miettinen M; Quezado M; Lebensohn AP; Aldape K; Agra M; Wagner C; Mallory Y; Hassan R; Ghafoor A
    J Thorac Oncol; 2022 Mar; 17(3):461-466. PubMed ID: 34628055
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
    Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S
    Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
    Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
    Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
    Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
    J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
    Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
    Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
    Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
    J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
    Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
    J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
    Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of second primary cancers after malignant mesothelioma and vice versa.
    Chen T; Kharazmi E; Lou J; Zhang X; Sundquist K; Hemminki K
    Cancer Lett; 2016 Aug; 379(1):94-9. PubMed ID: 27260871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.